The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.
Author(s): Wang W, Ma L, Zhang Y, Deng Q, Liu M, Liu L
Affiliation(s): Department of Evidence-Based Medicine, Cardiovascular Institute and Fuwai Hospital, Beijing, PR China.
Publication date & source: 2010-05-06, J Hum Hypertens., [Epub ahead of print]
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13 542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.Journal of Human Hypertension advance online publication, 6 May 2010; doi:10.1038/jhh.2010.45.